<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="346">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781026</url>
  </required_header>
  <id_info>
    <org_study_id>1208010666</org_study_id>
    <nct_id>NCT01781026</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases</brief_title>
  <official_title>A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the activity of vemurafenib in untreated melanoma
      brain metastases harboring BRAF mutations that are not amenable to stereotactic radiosurgery
      based on size, number of lesions or location, to measure cerebrospinal fluid (CSF) levels of
      vemurafenib as an indicator of central nervous system penetrance and to measure levels of
      vemurafenib in normal brain tissue and brain metastases in those in whom surgical management
      is feasible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II single arm study. After establishing eligibility, including at least one
      lesion that is not amenable to immediate stereotactic radiosurgery (SRS) or surgical
      resection based on size or location OR more than four lesions, patients will begin therapy
      with vemurafenib at 960 mg PO BID continuous dosing. Any lesions deemed in need of and
      amenable to urgent local therapy will be treated prior to initiation of vemurafenib,
      provided that patients have at least one untreated evaluable lesion.

      An MRI of the brain will be obtained after 4 weeks of vemurafenib therapy.  If the CNS index
      lesion(s) are stable or shrinking, an additional 4 weeks of vemurafenib will be given with
      the goal of providing definitive local therapy at 8 weeks.  If any lesion is growing after 4
      weeks, depending on the size and concern for symptom evolution, the PIs can either continue
      vemurafenib for 4 additional weeks or provide definitive local or regional therapy at the 4
      week mark in the form of surgery, LITT, SRS or WBRT. If a lesion becomes symptomatic at any
      time, local therapy can be administered, and the patient can remain on study provided that
      there is an additional untreated brain metastasis. If the patient receives LITT or has
      surgical resection, biopsy samples will be sent to the sponsor for measurement of
      vemurafenib levels in tumor and normal brain parenchyma.  Levels of pERK, as a surrogate for
      vemurafenib activity, will be measured in tumor samples. Vemurafenib will be held on the
      morning of radiation and restarted the following day. Vemurafenib dosing will not be held
      for surgery.

      All patients will be asked to have a lumbar puncture after 4 weeks of vemurafenib therapy.
      The next MRI of the brain will be obtained at week 8 and then every 8 weeks, along with body
      CT or PET/CT scans.

      If a patient is having overall shrinkage or stable disease in most CNS lesion(s), but if an
      individual cerebral metastases enlarges, local therapy can be done on study at any time if
      necessary. Patients will continue on vemurafenib until they have overall disease progression
      in either their CNS lesion(s) or in their systemic metastases as determined by modified
      MacDonald criteria (for cerebral lesion(s)) or RECIST criteria (for systemic disease),
      toxicities that preclude continuing the study drug, withdrawal from study, development of
      other severe illness, neurologic or systemic complications following local therapy to any
      lesion, termination of study, or death. Dose reductions for toxicities will be allowed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To determine the activity of vemurafenib in untreated brain metastases</measure>
    <time_frame>March 2014</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After the first 10 patients are entered onto the trial, an interim assessment will be conducted.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Melanoma [C04.557.465.625.650.510]</condition>
  <arm_group>
    <arm_group_label>This is a single arm trial</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental.  Vemurafenib 960 mg p.o. bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Single arm trial</description>
    <arm_group_label>This is a single arm trial</arm_group_label>
    <other_name>Zelboraf / RO5185426</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven metastatic melanoma with the B-raf V600E or V600K mutations.

          -  Untreated brain metastases

          -  At least one cerebral metastasis that is not amenable to stereotactic radiosurgery
             (SRS) or surgical resection  based on size or location OR four or more lesions

          -  Patients may be symptomatic at the time of enrollment, but after any necessary local
             therapy and/or corticosteroids, the patient should be asymptomatic when vemurafenib
             is initiated.

          -  Age &gt;18

          -  Adequate organ function

          -  ECOG performance status &lt; 3

          -  No prior therapies with selective inhibitors of mutated BRAF; other prior therapies
             must have been administered at least 4 weeks before administration of vemurafenib

          -  Life expectancy of at least 3 months

          -  Understanding and willingness to consent

          -  The use of corticosteroids to control cerebral edema or treat symptoms will be
             allowed

          -  A history of whole brain radiotherapy for brain metastases is allowed, but any stable
             lesion that was present at the time of WBRT will NOT be considered evaluable. A
             minimum of 1 week break will be required between prior WBRT and initiation of
             vemurafenib therapy.

        Exclusion Criteria:

          -  Presence of leptomeningeal disease based on positive CSF cytology.

          -  History or presence of clinically significant ventricular or atrial dysrhythmias â‰¥
             Grade 2 (NCI CTCAE, v4.0), Corrected QT (QTc) interval &gt;450 ms at baseline or history
             of congenital long QT syndrome

          -  Uncontrolled medical illness, such as uncontrolled infection, congestive heart
             failure and MI within 2 months.

          -  Second active, untreated malignancy, which is likely to result in the patient's
             demise prior to death from uncontrolled melanoma CNS metastases. This will be
             determined on a case by case basis by the PIs.

          -  Unwillingness to undergo monitoring for a secondary malignancy including clinical
             dermatologic examinations and head and neck examinations and serial CT scans.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harriet M Kluger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harriet Kluger, MD</last_name>
    <phone>203-737-5127</phone>
    <email>harriet.kluger@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mario Sznol, MD</last_name>
    <phone>203-737-2572</phone>
    <email>mario.sznol@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Smilow Cancer Hospital at Yale New Haven</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harriet Kluger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 2, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Harriet Kluger</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine, Oncology</investigator_title>
  </responsible_party>
  <keyword>B-raf V600E</keyword>
  <keyword>V600K mutation</keyword>
  <keyword>metastatic melanoma</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
